Tracking AI existential risk. Auto-aggregated headlines. Human-curated analysis.
AGGREGATING 47 SOURCES · UPDATED LIVE
Industry

Mind-altering substances are (still) falling short in clinical trials

Zac Boring March 20, 2026 1 min read
Read original source →

This week I want to look at where we are with psychedelics, the mind-altering substances that have somehow made the leap from counterculture to major focus of clinical research. Compounds like psilocybin—which is found in magic mushrooms—are being explored for all sorts of health applications, including treatments for depression, PTSD, addiction, and even obesity. Over…

By Jessica Hamzelou

Read the full article at MIT Technology Review →